Ivan V. Shashenkov, Md1, Sergey L. Babak1, Sergey A. Gabrusenko2, Andrey G. Maliavin1
1Moscow State University of Medicine and Dentistry, Moscow, Russia, 2National Research Medical Center of Cardiology, Moscow, Russia
The aim of the study was to assess the effects of the enhanced external counterpulsation (EECP) therapy in patients with ischemic chronic heart failure (CHF).
One hundred four (n=104) stable symptomatic CHF (NYHA, functional class I-II; 35%≤LVEF≤50%) subjects (84 male and 20 female; mean age 63±14,8) with prior anamnesis of CAD and at least one myocardial infarction were randomized in a 3:1 manner into either 35 1-hour 250-300 mm Hg sessions of EECP (n=78; 64 male, 16 female) or Sham-EECP (n=26; 22 male, 4 female). All subjects had been received optimal CHF and CAD drug therapy. At baseline, 3 months and 1 year after EECP course every subject was examined with echocardiography and 6-minute walk test.
All 78 active EECP treatment group subjects improved by at least 1 NYHA class, 69% of them had no heart failure symptoms post treatment (p<0.01). 92% of treatment group pts. had sustained NYHA class improvement at 1-year follow-up (p<0.01), compared with baseline. There was significant difference between LVEF 42±7,5% at baseline vs post-EECP LVEF 49±5,9% (p<0.01) in active EECP treatment group subjects. At the same time there were no significant changes of NYHA class and LVEF in Sham-EECP subjects. No one subject dies after one year of follow up.
Enhanced external counterpulsation (EECP) therapy sustainably improves NYHA functional class and LVEF in patients with ischemic CHF.